Cyclophosphamide is an alkylating chemotherapy agent used to treat various cancers and certain autoimmune diseases. It is available as a generic medication and marketed under brand names such as Cytoxan and Necyclar. In Hong Kong, cyclophosphamide is a prescription-only product supplied in oral pill form, commonly in 50 mg strengths. The drug is regulated by the Hong Kong Department of Health and must be prescribed by a qualified healthcare professional.
Cyclophosphamide is a pro-drug that requires metabolic activation. After oral ingestion, the liver’s cytochrome P450 enzymes convert it into 4-hydroxycyclophosphamide, which spontaneously forms phosphoramide mustard. This active metabolite cross-links DNA strands, interfering with replication and triggering apoptosis of rapidly dividing cells. Because malignant cells proliferate quickly, they are particularly vulnerable to this DNA damage. The drug also suppresses the immune system by impairing lymphocyte proliferation, which explains its use in severe autoimmune disorders.
Key pharmacokinetic points:
Cyclophosphamide has multiple FDA and EMA-approved indications that are also recognized by the Hong Kong regulatory framework:
The choice of cyclophosphamide, dosage, and treatment duration depend on disease stage, patient age, and concurrent therapies.
Cyclophosphamide is sometimes employed for conditions that lie outside its formal labeling. Robust clinical studies support some of these applications, but they remain off-label in Hong Kong:
Multiple sclerosis relapses - high-dose cyclophosphamide has been explored in refractory cases (RCTs show benefit, but use is limited to specialist centers). Off-label use requires medical supervision and individualized risk assessment.
Dermatologic vasculitis - case series demonstrate efficacy when conventional immunosuppression fails.
When considering off-label therapy, clinicians must weigh the evidence, potential toxicity, and patient preferences.
General Advice: Always provide a complete medication and supplement list to your healthcare provider before initiating cyclophosphamide.
Note: Dosing must be individualized; the information above provides a framework, not a prescription.
Patients should contact their clinician promptly if they notice unusual bleeding, persistent fever, or severe nausea despite anti-emetics.
This article provides educational information about cyclophosphamide and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Cyclophosphamide is often combined with other agents in multi-drug regimens to increase efficacy. However, each combination has specific dosing and monitoring requirements. A oncologist tailors the protocol to balance cancer control with toxicity risk.
Blood in the urine may signal hemorrhagic cystitis. Increase fluid intake immediately and contact your healthcare provider. They may prescribe mesna and adjust the cyclophosphamide dose.
Hair loss typically begins 2-4 weeks after starting therapy, though timing varies with dose and individual metabolism. The effect is usually reversible after treatment ends.
Inactivated vaccines, such as the flu shot, are generally safe for immunocompromised patients. Live vaccines should be avoided. Discuss vaccination timing with your oncologist.
There are no strict food restrictions, but a balanced diet supports overall health and may reduce nausea. Avoid grapefruit products if you are on CYP-interacting medications.
Yes. The drug can cause temporary or permanent infertility in both men and women, especially at high cumulative doses. Fertility preservation options should be discussed before treatment begins.
Fever over 38 °C, chills, persistent cough, or unexplained pain may indicate infection due to neutropenia. Seek medical care promptly, as infections can progress rapidly.
Both contain the same active ingredient, but oral dosing relies on gastrointestinal absorption, while IV dosing delivers the drug directly into the bloodstream. The choice depends on the clinical scenario and patient preference.
Maintain adequate hydration, carry a copy of your medication list, and be prepared for possible blood-count monitoring abroad. Some countries may have restrictions on importing chemotherapy agents; verify local regulations before travel.
